Kymera Therapeutics to Participate in Upcoming January and February Investor ConferencesGlobeNewsWire • 01/25/22
Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of DirectorsGlobeNewsWire • 01/18/22
Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines CompanyGlobeNewsWire • 01/10/22
Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022GlobeNewsWire • 01/04/22
Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D DayGlobeNewsWire • 12/16/21
Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/13/21
Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical OperationsGlobeNewsWire • 12/06/21
Kymera's Protein Degrader Platform Tech Moves Forward With 3rd Candidate; Updated Data On KT-474 In December At R&D DaySeeking Alpha • 11/30/21
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413GlobeNewsWire • 11/30/21
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingGlobeNewsWire • 11/12/21
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/10/21
Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business UpdateGlobeNewsWire • 11/10/21
Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting and the 63rd American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/04/21
Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor ConferencesGlobeNewsWire • 11/01/21
Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy VolunteersGlobeNewsWire • 10/27/21
Kymera to Hold Webcast and Conference Call Discussing Data from its KT-474 Phase 1 Trial to Be Presented at the 4th Annual Targeted Protein Degradation Summit on October 27thGlobeNewsWire • 10/20/21
Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation SummitGlobeNewsWire • 10/13/21
Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/06/21
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma ForumGlobeNewsWire • 07/12/21
Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 07/06/21
